Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Reduces thrombotic cardiovascular events (including stent thrombosis). Sold as Effient. Every FDA application for this active ingredient: 1 branded and 10 generic.
As of Nov 15, 2026, FDA lists 11 applications for Prasugrel Hydrochloride (sold as Effient), first approved Jul 10, 2009, with 2 new uses approved and 0 published complete response letters.
First approved: Jul 10, 2009
Applications: 11
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $22.6M
First approved in the EU: Feb 24, 2009
First approved in Japan: Mar 24, 2014
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Prasugrel HCl
Part D
$21.8M
-19%
99,822
Effient
Part D
$794K
-12%
174
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
PRASUGREL 10 MG TABLET: $0.256 per unitGeneric · -9% in a year
PRASUGREL 5 MG TABLET: $0.257 per unitGeneric · -27% in a year
First approved in Japan 56 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
EfientDrugs with a new indication and a new dosage for the prevention of recurrence after ischemic cerebrovascular disease (associated with large artery… · Daiichi Sankyo Company, Limited · Dec 24, 2021
Efient, new ingredientDrugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention… · Daiichi Sankyo Company, Limited · Mar 24, 2014 · Review report
Clinical Trials
15 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Mylan
Aurobindo Pharma
Accord Hlthcare
Lupin